Argus Research analyst David Toung downgrades Merck & Co (NYSE:MRK) from Buy to Hold.
Uncategorized
Argus Research Downgrades Merck & Co to Hold
Argus Research analyst David Toung downgrades Merck & Co (NYSE:MRK) from Buy to Hold.
Related Posts
Check Out What Whales Are Doing With PFE
A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer.
Looking at options history for Pfizer (NYSE:PFE) we detected 16 strange trades.
JP Morgan Maintains Neutral on Moelis & Co, Lowers Price Target to $40
JP Morgan analyst Kenneth Worthington maintains Moelis & Co (NYSE:MC) with a Neutral and lowers the price target from $42 to $40.
JMP Securities Maintains Market Outperform on Braze, Lowers Price Target to $46
JMP Securities analyst Patrick Walravens maintains Braze (NASDAQ:BRZE) with a Market Outperform and lowers the price target from $52 to $46.